跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,815 条关于
“Xanomeline/trospium chloride”
全部
1,815
临床试验
1,362
药物
308
机构
7
资讯
138
去年
Xanomeline/Trospium Chloride (COBENFY™) Approved for Schizophrenia Treatment
去年
Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins
去年
Xanomeline-Trospium Shows Consistent Efficacy in Schizophrenia Across Pooled Phase 3 Trials
去年
Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress
2年前
FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors
去年
Cobenfy Shows Sustained Efficacy and Safety in Long-Term Schizophrenia Trials
去年
Zai Lab's KarXT Shows Positive Phase 3 Results for Schizophrenia Treatment in China
去年
Schizophrenia Treatment Targeting Cholinergic Receptors Receives FDA Approval
去年
Zai Lab's KarXT Shows Positive Phase 3 Results for Schizophrenia Treatment in China
去年
Zai Lab's KarXT Shows Positive Phase 3 Results in China for Schizophrenia
第 1 页，共 14 页
上一页
下一页
